A multi-centre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer.

Like Comment
The optimal duration of filgrastim as primary febrile neutropenia (FN) prophylaxis in early breast cancer (EBC) patients is unknown, with 5, 7 or 10 days being commonly prescribed. This trial evaluates whether 5 days of filgrastim was non-inferior to 7/10 days.In this randomised, open-label trial, EBC patients who were to receive filgrastim as primary FN prophylaxis were randomly allocated to 5 vs 7 vs 10 days of filgrastim for all chemotherapy cycles. A protocol amendment in November 2017 allowed subsequent patients (N=324) to be randomised to either 5 or 7/10 days. The primary outcome was a composite of either FN or treatment-related hospitalisations. Secondary outcomes included chemotherapy dose reductions, delays, and discontinuations. Analyses were performed by per protocol (primary) and intention-to-treat and the non-inferiority margin was set at 3% for the risk of having FN and/or hospitalisation per cycle of chemotherapy.Patient (N=466) were randomized to receive 5 (184, 39.5%), or 7/10 (282, 60.5%) days of filgrastim. In our primary analysis, the difference in risk of either FN or treatment-related hospitalisation per cycle was -1.52% (95%CI: -3.22% to 0.19%) suggesting non-inferiority of a 5-day filgrastim schedule compared to 7/10-days. The difference in events per cycle for FN was 0.11% (95%CI: -1.05 to 1.27) while for treatment-related hospitalisations it was -1.68% (95%CI: -2.73% to -0.63%). The overall proportions of patients having at least one occurrence of either FN or treatment-related hospitalization were 11.8% and 14.96% for the 5- and 7/10-day groups respectively (Risk Difference: -3.17%, 95%CI: -9.51% to 3.18%).Five days of filgrastim was non-inferior to 7/10 days. Given the cost and toxicity of this agent, 5 days should be considered standard of care.


Click here to read the full article @ Annals of oncology : official journal of the European Society for Medical Oncology
Go to the profile of ClinOwl

ClinOwl

The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
1805 Contributions
1 Followers
0 Following

No comments yet.